State-of-the-Art Imaging of Movement Disorders
Duygu Tosun1
1University of California, San Francisco, San Francisco, CA, United States

Synopsis

Neuroimaging offers a non-invasive approach to examining the potential utility of a vast number of functional and structural brain characteristics as biomarkers. Neuroimaging has been used in Parkinson disease research for 30 years, but no guidelines have yet endorsed its routine use in clinical settings. We will focus on the role of multimodal neuroimaging in differential diagnosis, monitoring disease progression, and monitoring non-motor cognitive dysfunction.

The hallmark pathology of Parkinson's Disease, one of a number of conditions on the spectrum of movement disorders, is the loss of dopaminergic neurons in the substantia nigra pars compacta, but the disease manifests with a diversity of symptoms referable to multi-system neuropathology. Clinical symptoms manifests through hallmark motor symptoms, often accompanied by a range of non-motor symptoms. The corresponding neurodegeneration occurring throughout the pre-motor period particularlt represents a missed opportunity for early therapeutic intervention that may significantly slow or halt the progression of disease related decline. Putative delay between the onset of the neurodegenerative process and the onset of motor symptoms, creating an urgent need to develop biomarkers that may yield early disease detection. Neuroimaging offers a non-invasive approach to examining the potential utility of a vast number of functional and structural brain characteristics as biomarkers. Neuroimaging has been used in Parkinson disease research for 30 years, but no guidelines have yet endorsed its routine use in clinical settings. We will focus on the role of multimodal neuroimaging in differential diagnosis, monitoring disease progression, and monitoring non-motor cognitive dysfunction.

Acknowledgements

No acknowledgement found.

References

1: Lauretani F, Longobucco Y, Ravazzoni G, Gallini E, Salvi M, Maggio M. Imaging the Functional Neuroanatomy of Parkinson's Disease: Clinical Applications and Future Directions. Int J Environ Res Public Health. 2021 Feb 28;18(5):2356. doi: 10.3390/ijerph18052356. PMID: 33670940; PMCID: PMC7967767.

2: Carey G, Görmezoğlu M, de Jong JJA, Hofman PAM, Backes WH, Dujardin K, Leentjens AFG. Neuroimaging of Anxiety in Parkinson's Disease: A Systematic Review. Mov Disord. 2021 Feb;36(2):327-339. doi: 10.1002/mds.28404. Epub 2020 Dec 2. PMID: 33289195; PMCID: PMC7984351.

3: Thomsen BLC, Teodoro T, Edwards MJ. Biomarkers in functional movement disorders: a systematic review. J Neurol Neurosurg Psychiatry. 2020 Dec;91(12):1261-1269. doi: 10.1136/jnnp-2020-323141. Epub 2020 Oct 21. PMID: 33087421.

4: Cho SJ, Bae YJ, Kim JM, Kim D, Baik SH, Sunwoo L, Choi BS, Kim JH. Diagnostic performance of neuromelanin-sensitive magnetic resonance imaging for patients with Parkinson's disease and factor analysis for its heterogeneity: a systematic review and meta-analysis. Eur Radiol. 2021 Mar;31(3):1268-1280. doi: 10.1007/s00330-020-07240-7. Epub 2020 Sep 4. PMID: 32886201.

Proc. Intl. Soc. Mag. Reson. Med. 29 (2021)